“Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon”, revista-de-medicina, vol. 40, no. 3, pp. 6–12, Apr. 2017, doi: 10.15581/021.8892.